{"id":"W3186412928","doi":"10.1016/j.cgh.2021.07.038","title":"Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Takeda Canada; MedImmune; Diagnostic Services Manitoba; AbbVie Canada; Seres Therapeutics; Nippon Kayaku; Boehringer Ingelheim; Janssen Pharmaceuticals; Gilead Sciences; Roche; Teva Pharmaceutical Industries; Ferring Pharmaceuticals; Novartis; Pfizer; Shire; Eli Lilly and Company; Schering-Plough; AbbVie; Abbott Laboratories","keywords":"Vedolizumab; Medicine; Infliximab; Ulcerative colitis; Internal medicine; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00206308,0.0006200091,0.00382943,0.0006829788,0.0003269244,0.001108687,0.0007062228,0.001545664,0.003603911],"category_scores_gemma":[0.002973327,0.0003960357,0.002139316,0.0005791042,0.0008954041,0.001489549,0.0003319169,0.001964014,0.0006099336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006361191,"about_ca_system_score_gemma":0.0003666096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007305163,"about_ca_topic_score_gemma":0.001374993,"domain_scores_codex":[0.9986498,0.0007803535,0.0001224285,0.0001251704,0.00009869951,0.0002235959],"domain_scores_gemma":[0.9977958,0.001201601,0.0002824335,0.000179256,0.0000966348,0.0004443209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9674369,0.001881813,0.00191198,0.0003747087,0.0008710908,0.0001003664,0.00006418995,0.000323809,0.004393488,0.00009551923,0.0001595426,0.02238661],"study_design_scores_gemma":[0.4072529,0.5256751,0.05454987,0.0002093196,0.004427799,0.0003854563,0.0002760669,0.001319073,0.003574697,0.0004403103,0.001810789,0.00007866355],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838638,0.01312102,0.00016615,0.0003190793,0.0002736895,0.00009447099,0.0003195138,0.00002349437,0.001818652],"genre_scores_gemma":[0.9960973,0.002034739,0.0001827533,0.0001825582,0.0002664878,0.00006863994,0.0004209998,0.00000740174,0.0007392478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00382943,"threshold_uncertainty_score":0.01205629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03966503244793541,"score_gpt":0.3515347577470193,"score_spread":0.3118697252990839,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}